Every drug ends up with three distinct names: a chemical name describing its molecular structure, a generic name used by doctors and pharmacists worldwide, and a brand name chosen by the company selling it. Each one is assigned through a different process, at a different time, and by a different group. The system is more regulated than most people realize, with safety checks built in at every stage to prevent dangerous mix-ups at the pharmacy counter.
The Three Names Every Drug Gets
A drug’s chemical name comes first and describes exactly what the molecule looks like. These names follow strict chemistry conventions and tend to be long, unwieldy strings that no one outside a lab would use. Acetaminophen’s chemical name, for instance, is N-acetyl-para-aminophenol. Many of the oldest drugs we still use today actually got their common names by shortening their chemical names, which is how N-acetyl-para-aminophenol became acetaminophen.
The generic name is the one you see on pharmacy labels and in medical references. It’s nonproprietary, meaning no company owns it. Since the 1960s, the United States Adopted Names (USAN) Program has been assigning these names to every active drug ingredient sold in the United States. Internationally, the World Health Organization runs a parallel system called International Nonproprietary Names (INN), which has been operating since 1953. The goal of both systems is to give each substance one unique, universally recognized name. Sometimes the two systems don’t perfectly align: what Americans call acetaminophen is known as paracetamol in most other countries, though both names predate the current naming programs.
The brand name is the marketing name a pharmaceutical company chooses and trademarks. A single generic drug can have multiple brand names if different companies sell it. Brand names go through their own approval process with both the U.S. Patent and Trademark Office and the FDA, and getting a trademark registered doesn’t guarantee the FDA will approve that same name. The two agencies evaluate names with different criteria, so companies need to satisfy both.
How Generic Names Are Chosen
The USAN Council describes its naming process as a “negotiation.” It starts when a drug company files an application requesting a name for a new substance. After the USAN staff confirms the application is complete and the substance meets all prerequisites, the Council evaluates potential names against several criteria: whether the name reflects what the drug does, how well it fits into existing naming conventions for similar drugs, how easily it translates into other languages, and how simple it is to pronounce and remember.
The Council then votes on a proposed name and sends its suggestion to the drug company for review. From there, the name goes through international clearance with the WHO’s INN Expert Group. All three parties, the sponsoring company, the USAN Council, and the INN group, must agree on a single name before it becomes official. This back-and-forth can take time, and pharmaceutical companies sometimes push for names that subtly suggest positive qualities about their drug. The USAN Council has pushed back on this, prioritizing patient safety and clarity over marketing appeal.
The WHO places all international nonproprietary names in the public domain, meaning no company can own or restrict use of a generic name. The INN system only assigns names to single, well-defined substances that can be precisely identified by their chemical formula. Mixtures of substances, herbal products, and homeopathic remedies don’t get INNs. Substances with a long history of medical use under well-established names, like morphine or codeine, keep their existing names rather than receiving new ones.
What Those Word Endings Mean
One of the most useful features of the generic naming system is that drugs in the same family share a common “stem,” usually a suffix. If you know the pattern, you can identify what a drug does just by reading its name. Here are some of the most recognizable ones:
- -statin (cholesterol-lowering drugs): atorvastatin, rosuvastatin
- -olol (beta-blockers for blood pressure and heart rate): metoprolol, atenolol
- -mycin or -floxacin (antibiotics): azithromycin, ciprofloxacin
- -oxetine (certain antidepressants): fluoxetine, duloxetine
- -terol (bronchodilators that open airways): albuterol, formoterol
- -azole (antacids and antifungals): omeprazole, fluconazole
- -sone or -solone (corticosteroids): prednisone, prednisolone
- -arin (blood thinners): warfarin, heparin
- -caine (local anesthetics): lidocaine, benzocaine
- -apine or -azine (antipsychotics): olanzapine, quetiapine
These stems are assigned deliberately by the USAN Council and the WHO so that healthcare professionals anywhere in the world can immediately recognize a drug’s class. When a company proposes a generic name, it needs to use the correct stem for that drug’s mechanism of action.
When Each Name Gets Assigned
Drug naming follows the clinical trial timeline. The earliest a U.S. company can request a generic name is during Phase 1 trials, when a drug is first being tested in small groups of healthy volunteers for basic safety. In practice, most companies wait until Phase 3, which involves large-scale studies testing whether the drug actually works. By that point, firms are publishing earlier study results and want an official name to use in their publications.
The generic name is typically adopted and published during this Phase 3 window. Companies based outside the U.S. that already have an INN from the WHO apply for a USAN at this stage as well. Brand names follow a slightly different track: planned trade names can be filed for FDA review during Phase 3, along with supporting documentation. This means the generic and brand names are often being developed in parallel during the final stretch before a drug reaches the market.
How Brand Names Get Approved
Choosing a brand name is equal parts marketing and safety engineering. The FDA evaluates every proposed brand name before a drug can be sold under it, looking at both promotional concerns (does the name overstate what the drug does?) and safety concerns (could it be confused with another drug?).
The safety review is especially rigorous. The FDA runs proposed names through the Phonetic and Orthographic Computer Analysis (POCA) program, software that uses an algorithm to score how similar a proposed name looks and sounds compared to every existing drug name in its databases. A name that scores too close to an existing drug gets flagged, because if a pharmacist misreads a prescription for “Celebrex” as “Celexa,” the patient could receive an entirely wrong medication.
Beyond the computer analysis, the FDA uses a method called failure modes and effects analysis to identify other ways a name could cause errors. A name might suggest incorrect ingredients, imply the wrong dosing frequency, or hint at the wrong route of administration (swallowed versus injected, for example). The USAN Program runs its own parallel screening using searches of existing drug name databases to catch conflicts on the generic side as well. Companies that file an “intent to use” trademark with the Patent and Trademark Office can secure a trademark before FDA approval, but they still need the FDA’s sign-off before that name appears on a bottle.
Why Some Names Still Cause Confusion
Despite all these safeguards, look-alike and sound-alike drug names remain a real source of medication errors. The sheer number of drugs on the market, combined with the limited number of short, pronounceable letter combinations available, means near-misses are inevitable. The FDA has rejected roughly 35% of proposed brand names in some years, often sending companies back to the drawing board multiple times.
This is also why generic names occasionally seem unnecessarily complicated. The USAN Council carefully screens every prefix and combination against databases of existing names, which means a simple, intuitive name often can’t be used because it’s already too close to something else. The result is a system that prioritizes distinguishability over memorability, a tradeoff that makes more sense when you consider that a single misread syllable at the pharmacy could send someone home with the wrong drug.